A rational substrate-based design approach successfully yielded the first class of potent, selective, and picomolar inhibitors of ACE2.
The study reports the successful rational design and synthesis of the first class of potent, picomolar ACE2 inhibitors.
Absolute Event Rate: 0% vs 0%
Angiotensin-converting enzyme-related carboxypeptidase (ACE2) is a recently identified zinc metalloprotease with carboxypeptidase activity that was identified using our genomics platform. We implemented a rational design approach to identify potent and selective ACE2 inhibitors. To this end, picomolar inhibitors of ACE2 were designed and synthesized.
Dales et al. (Thu,) reported a other. A rational substrate-based design approach successfully yielded the first class of potent, selective, and picomolar inhibitors of ACE2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: